Loading clinical trials...

Lung Cancer Exercise Training Study | Clinical Trials | Clareo Health

COMPLETEDNA

Lung Cancer Exercise Training Study

Lung Cancer Exercise Training Study: A Randomized Trial of Aerobic Training, Resistance Training, or Both in Lung Cancer Patients

NCT01068210•Memorial Sloan Kettering Cancer Center

View on ClinicalTrials.gov

Summary

The purpose of the study is look at the effects of different types of exercise training with a stretching group and its effect on lung cancer patients. Subjects will take part in a 16 week training intervention that can consist of aerobic, resistance, aerobic \& resistance, or a control group. Pre and Post testing will include stress tests, echos, blood, and urine samples.

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Signed informed consent prior to initiation of study-related procedures
•Age 21 - 80 years
•Weight \< 205 kgs
•ECOG ≤ 1
•Diagnosed with histologically confirmed lung cancer, regardless of disease stage and receiving any prior line of any therapy in the context of metastatic disease
•An interval of at least three months following the completion of primary resection, if appropriate
•An interval of no longer than ten years following completion of primary therapy, if appropriate
•Life expectancy ≥ 4 months
•Performing less than 150 minutes of structured moderate-intensity or strenuous-intensity exercise per week
•Exercise intolerance (i.e., patients must have a VO2peak below that predicted for active age and sex-matched individuals)
+9 more criteria

Exclusion Criteria

•Presence of a concurrent, actively treated other malignancy, or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer);
•Room air desaturation at rest ≤ 85%;
•Mental impairment leading to inability to cooperate.
•Any of the following absolute contraindications to cardiopulmonary exercise testing:
•* Acute myocardial infarction (within 3-5 days of any planned study procedures);
•* Unstable angina;
•* Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
•* Recurrent syncope;
•* Active endocarditis;
•* Acute myocarditis or pericarditis;
+9 more criteria

Locations (1)

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Key Dates

Start Date

October 1, 2015

Primary Completion Date

March 29, 2024

Completion Date

March 29, 2024

Last Updated

May 4, 2025

Enrollment

110

ACTUAL participants

Conditions

Lung Cancer

Interventions

Aerobic Training

BEHAVIORAL

Progressive Stretching

BEHAVIORAL

Resistance Training

BEHAVIORAL

Aerobic and Resistance Training

BEHAVIORAL

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

View study

RECRUITING

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Lung Cancer Exercise Training Study

Inclusion Criteria

Exclusion Criteria

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Magnetic Resonance Imaging of the Lung: Oncological Applications

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing